18
Participants
Start Date
June 1, 2020
Primary Completion Date
May 31, 2022
Study Completion Date
August 1, 2023
Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
tislelizumab (BeiGene, China) combined with PD-1 inhibitor
The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
Zhejiang Hospital, Hangzhou
Zhejiang Hospital
OTHER
Pengyuan Liu
OTHER